Patients who were diagnosed by the histologic, cytologic diagnosis of IIIB (malignant hydrothorax or hydropericardium) or IV non-small cell lung cancer
≥ 18 years old
patients who have received more than one regimen of platinum-based chemotherapy; patients who have received EGFR monoclonal treatment could also be enrolled
At least one target lesion diameter spiral CT ≥ 1 cm, or the common CT ≥ 2 cm, and can be measured by imaging tools
have an interval of more than 4 weeks from the last chemo- or radio-therapy; 2 weeks from the last targeted therapy
ECOG 0-2
Expected life time longer than 3 months
Normal laboratory values:
* leucocyte≥ 4×109/L
* neutrophil≥ 1.5×109/L
* platelet≥90×109/L
* Hemoglobin≥ 9g/L
* ALT and AST ≤3×ULN (≤5×ULN if liver metastasis)
* serum creatinine\<1.5 mg/dl
* bilirubin \<1.5×ULN
No allergy to biological drug
Sign the consent forms
You may not be if
Patients who have previously received Docetaxel or anti-VEGF inhibitors
Severe symptomatic heart disease
Female patients during their pregnant and lactation period, or patients without contraception
Severe uncontrolled infection
Uncontrolled neurologic or psychiatric disease; Uncontrolled primary or metastatic brain tumor
Patients with other malignant tumor,except for basal cell carcinoma,squamous cell carcinoma and carcinoma in situ
Patients have accepted other clinical trials
Clareo Health | Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients
